{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T01:59:13Z","timestamp":1772589553087,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,4,22]],"date-time":"2008-04-22T00:00:00Z","timestamp":1208822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:p> <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Rosiglitazone is able to increase serum adiponectin levels significantly in Type 2 diabetic patients.<\/jats:p><jats:p>\u2022\u2003The role of genetic factors that determine the marked interindividual variability in glucose\u2010lowering efficacy of rosiglitazone in Chinese patients is not known.<\/jats:p><jats:p>\u2022\u2003The current study was designed to evaluate the impact of the adiponectin common allele <jats:italic>45T\/G<\/jats:italic> and \u2212<jats:italic>11377C\/G<\/jats:italic> polymorphisms on the response to rosiglitazone monotherapy in Chinese patients with Type 2 diabetes (T2D).<\/jats:p><jats:p> <jats:bold>WHAT THIS STUDY ADDS<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003The genetic polymorphisms of adiponectin alleles <jats:italic>45T\/G<\/jats:italic> and \u2212<jats:italic>11377C\/G<\/jats:italic> as well as their common diplotypes are significantly associated with an attenuated fasting plasma glucose, postprandial plasma glucose and homeostasis model assessment for insulin resistance as well as an enhanced adiponectin concentration in Chinese patients with T2D after rosiglitazone treatment.<\/jats:p><jats:p><jats:bold>AIMS<\/jats:bold> The aim of the present study was to evaluate the impact of adiponectin allele <jats:italic>T45G<\/jats:italic> and <jats:italic>C\u201011377<\/jats:italic>G genetic polymorphisms on efficacy of rosiglitazone in Chinese patients with type 2 diabetes (T2D).<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold> Patients with T2D (n\u2003=\u2003255) and 120 healthy volunteers were enrolled to identify <jats:italic>45T\/G<\/jats:italic> and <jats:italic>\u201311377C\/G<\/jats:italic> genotypes by polymerase chain reaction\u2010restriction fragment length polymorphism assay. Forty\u2010two T2D patients with different <jats:italic>45T\/G<\/jats:italic> or <jats:italic>\u201311377C\/G<\/jats:italic> genotypes received orally rosiglitazone as a single\u2010dose therapy (4\u2003mg day\u20101 p.o.) for 12 weeks. Serum triglyceride, fasting plasma glucose (FPG), postprandial plasma glucose (PPG), glycated hemoglobin, fasting serum insulin, postprandial serum insulin, total cholesterol, homeostasis model assessment for insulin resistance (HOMA\u2010IR), low\u2010density lipoprotein\u2010cholesterol, high\u2010density lipoprotein\u2010cholesterol (HDL\u2010c) and adiponectin concentration were determined before and after rosiglitazone treatment.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold> We showed an attenuated rosiglitazone effect in patients with \u201311377CG+GG heterozygote genotype on FPG, PPG, HOMA\u2010IR compared with \u201311377CC homozygote genotype. However, we found an enhanced rosiglitazone effect on serum adiponectin concentration in patients with \u201311377CC homozygote genotype compared with \u201311377CG+GG heterozygote genotype (<jats:italic>P<\/jats:italic>\u2003=\u20030.000) and in patients with 45TG\u2003+\u2003GG heterozygote genotype compared with 45TT homozygote genotype (<jats:italic>P<\/jats:italic>\u2003=\u20030.018). Finally, our results showed that there was an enhanced effect in patients with <jats:italic>\u201311377\/45<\/jats:italic> CGTT diplotype compared with other discovered diplotypes on FPG (<jats:italic>P<\/jats:italic>\u2003=\u20030.001) and PPG (<jats:italic>P<\/jats:italic>\u2003=\u20030.003) after rosiglitazone treatment.<\/jats:p><jats:p><jats:bold>CONCLUSIONS<\/jats:bold> These data suggest that the adiponectin allele <jats:italic>45T\/G<\/jats:italic> and \u2013<jats:italic>11377C\/G<\/jats:italic> polymorphisms are significantly associated with the therapeutic efficacy of multiple\u2010dose rosiglitazone in Chinese patients with T2D.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2008.03145.x","type":"journal-article","created":{"date-parts":[[2008,4,22]],"date-time":"2008-04-22T21:01:27Z","timestamp":1208898087000},"page":"917-926","source":"Crossref","is-referenced-by-count":54,"title":["The association of adiponectin allele <i>45T\/G<\/i> and \u2212<i>11377C\/G<\/i> polymorphisms with Type 2 diabetes and rosiglitazone response in Chinese patients"],"prefix":"10.1111","volume":"65","author":[{"given":"Hong","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi\u2010Cheng","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji\u2010Ye","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai\u2010Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying\u2010Zi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi\u2010Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong\u2010Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao\u2010Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,4,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.45.26746"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1999.0255"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.2.376"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1996.0587"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.18.10697"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.5.1139"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.1.37"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(03)00074-X"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-002-0409-4"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.7.2306"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-003-1050-7"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.2.536"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/11.21.2607"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2004.08.014"},{"key":"e_1_2_6_17_2","volume-title":"Molecular Cloning: a Laboratory Manual","author":"Sambrook J","year":"1989"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/379378"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-005-1260-9"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.2007.S31"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrg775"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.5551\/jat.14.19"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-003-1136-2"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.7.1655"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.10.2968"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo.143.3.8662"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2008.03145.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2008.03145.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T14:12:46Z","timestamp":1697379166000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2008.03145.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,22]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1111\/j.1365-2125.2008.03145.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03145.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,22]]}}}